The platform will offer antibiotics and GLP-1 medicines used in obesity and diabetes treatments, including Ozempic. Customers must upload prescriptions before a Mercado Livre pharmacist approves orders.
The move extends the company’s pharmacy strategy beyond non-prescription products. It also brings major drugstore chains onto the marketplace, giving them access to Mercado Livre’s traffic and delivery network.
Prescription medicines add a new competitive test
Mercado Livre’s own São Paulo pharmacy will handle the initial sales. A pharmacist will review prescriptions before the company releases each purchase for fulfilment.
The launch begins in São Paulo and its metropolitan area. The company plans a gradual expansion into other regions.
Meanwhile, three unnamed pharmacy chains are expected to join the marketplace by the end of October. Mercado Livre aims to have 20 partner pharmacies operating on the platform by year-end.
That model could shift the competitive focus from store networks towards digital reach. Pharmacy chains retain their products and operating licences. However, Mercado Livre controls the customer interface, search traffic and delivery proposition.
The company says the partnerships should complement existing retail operations. Its marketplace already hosts products from other large retailers, including Casas Bahia and Magazine Luiza.
The strategy also fits Brazil’s changing regulatory framework. A March 2026 law allowed licensed pharmacies to hire e-commerce platforms for logistics and delivery, subject to health rules.
Anvisa, Brazil’s health regulator, remains central to the operating model. The company’s prescription process places a pharmacist between the customer upload and order approval.
What does the deal mean for investors?
The market reaction showed the threat investors see in the platform’s expansion. Pague Menos shares fell 8% on 24 September, according to market data reported by Neofeed.
RD Saúde shares dropped 5.38%, while Panvel shares declined 4.9% during the same session. The falls indicate that investors expect stronger digital competition across Brazil’s pharmacy sector.
Mercado Livre shares also fell 2.51% in New York, leaving the company valued at US$88.9bn, according to supplied company-market data.
The company will pair prescription medicines with deliveries within 60 minutes in São Paulo. The service will cover medicines, food and other products.
That speed could matter most for repeat purchases and urgent household needs. It also gives partner pharmacies a way to compete without building equivalent logistics infrastructure.
The broader investment signal is clear: Mercado Livre is moving from marketplace distribution into regulated, higher-frequency categories. Pharmacy chains must now defend customer relationships while using external platforms to extend reach.
For investors, the next test will be prescription volumes, delivery reliability and partner-chain adoption across São Paulo before the model expands elsewhere.
Quick answers
Mercado Livre will begin selling prescription medicines in São Paulo and its metropolitan area on 25 September, with a planned gradual expansion into other regions.
Pague Menos fell 8%, RD Saúde dropped 5.38%, and Panvel declined 4.9% on 24 September, according to market data reported by Neofeed.
Customers must upload their prescription to the platform, where a Mercado Livre pharmacist reviews and approves the order before it is released for fulfilment.
